Merck Sharp & Dohme

Rahway, NJ, United States

1

Total Recalls

0

Class I Recalls

0

Ongoing Recalls

Recalls by Merck Sharp & Dohme

FDA Drug Class II Terminated

Zerbaxa (ceftolozane and tazobactam) 1.5g per vial for injection, Single-Dose vial, Rx only, Manuf. for: Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc., NDC 67919-030-01

December 21, 2020 Merck Sharp & Dohme 106,503 vials units